Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GI-101 |
| Synonyms | |
| Therapy Description |
GI-101 is a bispecific protein comprising the extracellular domain of CD80, which binds to and inhibits CTLA4, and an IL-2 variant that binds to IL2RB, which potentially leads to increased antitumor immune response and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6529). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GI-101 | GI 101|GI101 | CTLA4 Inhibitor 4 | GI-101 is a bispecific protein comprising the extracellular domain of CD80, which binds to and inhibits CTLA4, and an IL-2 variant that binds to IL2RB, which potentially leads to increased antitumor immune response and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6529). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04977453 | Phase Ib/II | GI-101 GI-101 + Pembrolizumab GI-101 + Lenvatinib | GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | Recruiting | USA | 1 |